ATRC News and Press, AtriCure Inc. From 01/25/24

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results ...

2024-01-16 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-08 12:01:16 ET More on AtriCure AtriCure: Appeal Lures For This Cure AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript AtriCure defended at UBS despite Medtronic’s rival product Needham says Medtronic could create overhang on AtriCure shar...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2023 and provided...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman’s long and d...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthc...

2023-11-29 08:53:57 ET More on AtriCure AtriCure: Appeal Lures For This Cure AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript Needham says Medtronic could create overhang on AtriCure shares Seeking Alpha’s Quant Rating on AtriCure Histori...

2023-11-28 15:12:37 ET More on AtriCure, Medtronic, etc. 3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic Medtronic plc (MDT) Q4 2024 Earnings Call Transcript Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings Bigges...

2023-11-26 22:07:39 ET Summary The article discusses the factors that have led to the undervaluation of the MedTech sector, including the rise in interest rates, opposition to corporate acquisitions by the FTC, and the impact of GLP-1-based treatments. I defend the importance of M...